A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group

J Mackay, D A Cameron, J Gardiner, T Leonard, L E Lee, R C Leonard

Research output: Contribution to journalArticlepeer-review

Abstract

We have previously shown that 5-fluorouracil (5-FU) given by continuous infusion is well tolerated and active in the treatment of breast cancer [1, 2]. We found that given infusional 5-FU could produce responses in patients whose disease was resistant to bolus 5-FU and speculated that it could be combined safely with methotrexate/cyclophosphamide in a manner analogous to i.v. CMF bolus. Using a modification of the i.v. CMF regimen, comprising a standard dosage of bolus cyclophosphamide at 750 mg/m2 and bolus methotrexate at 50 mg/m2 given every 3 weeks we altered the continuously infused 5-FU schedule to 200 mg/m2/24 hours and treated 28 patients of whom 23 had had previous chemotherapy (18 containing anthracycline, 4 bolus CMF and 19 infusional 5-FU alone or in combination with other drugs) and 4 post menopausal patients with locally advanced breast cancer.
Original languageEnglish
Pages (from-to)409-11
Number of pages3
JournalAnnals of Oncology
Volume7
Issue number4
Publication statusPublished - Apr 1996

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Cisplatin
  • Female
  • Fluorouracil
  • Humans
  • Infusions, Intravenous
  • Methotrexate
  • Middle Aged
  • Pilot Projects

Fingerprint

Dive into the research topics of 'A pilot study of infusional CMF (CMF-inf): active and well tolerated in breast cancer. The Edinburgh Breast Group'. Together they form a unique fingerprint.

Cite this